Clearside Biomedical, Inc. - Common Stock (CLSD)

Clearside Biomedical's CLS-AX Phase 2b trial for wet AMD met primary and secondary endpoints, showing stable vision and reduced injection frequency by 84% over 24 weeks, with no serious adverse events reported.

CLSD stock results show that Clearside Biomedical beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS Microinjector and strategic partnerships.

CLSD stock results show that Clearside Biomedical missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Stocks under $7 have greater potential for substantial gains because they start off with lower valuations. Here are some of the best now.

Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money.

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.

As of Jan. 22, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Regenxbio's latest trial data on ABBV-RGX-314 reveal 80% reduction in injection rate, 50% injection-free, and no intraocular inflammation.

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.